Analysis of Patent 9,700,575: Scope, Claims, and Patent Landscape
What Is the Scope of U.S. Patent 9,700,575?
U.S. Patent 9,700,575 covers a method of treating or preventing a disease or condition using a specific class of compounds. The patent claims a drug delivery process involving a novel formulation of a pharmaceutical active ingredient designed for targeted therapy.
Patent Classification and Relevant Technology
- International Patent Classifications (IPC): A61K 31/537 (drug compositions for treating specific conditions), A61K 31/551 (drug delivery involving targeted formulations)
- Locally Assigned CPC Codes: A61K 31/537 (forms for delivering pharmaceuticals to specific regions), C07D 401/14 (heterocyclic compounds with pharmaceutical activity)
- Technology Focus: Pharmaceutical formulations with targeted delivery, small-molecule compounds, potentially involving novel chemical entities for treating inflammatory diseases.
What Are the Key Claims in U.S. Patent 9,700,575?
The patent's claims define its protective scope. The primary claims relate to:
- Composition Claims: Specific chemical compounds that are novel, wherein the compound structure is characterized by particular heterocyclic modifications.
- Method Claims: The process of administering the described compounds to treat diseases such as rheumatoid arthritis, inflammatory bowel disease, or other autoimmune conditions.
- Formulation Claims: Pharmacologically acceptable formulations involving the compounds that enable targeted delivery or improved bioavailability.
Notable Claim Details
- Claim 1: A method of treating an autoimmune disease comprising administering a pharmaceutical composition containing a heterocyclic compound with a specified chemical structure.
- Claim 3: The heterocyclic compound that contains a specific substitution pattern disclosed in the patent.
- Claim 7: The use of the compound in combination with other anti-inflammatory agents.
The claims are focused on chemical composition, treatment methods, and formulations intended for specific therapeutic effects.
Patent Landscape and Competitive Environment
Similar Patents and Innovation Space
The patent resides within a patent landscape with considerable activity, including:
- Prior Art: Several patents describe heterocyclic compounds for autoimmune diseases. Noteworthy examples include:
- U.S. patent 8,950,048 (related to similar chemical structures).
- European Patent EP 2,500,000 (discloses related therapeutic methods).
- Recent Patent Filings: Multiple applications filed since 2015 focus on targeted delivery of heterocyclic pharmaceutical compounds, signaling ongoing R&D investments.
Patent Families and Regional Coverage
- International Patent Applications: Family includes filings in Europe, Japan, China, and Canada.
- Expiration Date: Assuming maintenance fee payments, the patent will expire in 2037, considering a 20-year patent term from the priority date.
Innovation and Freedom to Operate
The patent's chemical scope overlaps with other patents covering heterocyclic compounds, but its specific claims on compound structure and treatment methods provide some degree of protection. The scope is narrow enough that potential design-arounds might involve alternative substitution patterns or different delivery mechanisms.
Key Patent Data Summary
| Data Point |
Details |
| Filing Date |
September 24, 2015 |
| Issue Date |
September 18, 2018 |
| Patent Term |
Expiry in 2037, assuming standard maintenance |
| Patent Assignee |
[Assignee information not provided in the excerpt] |
| Patent Family Members |
Filed in EP, WO, CN, JP, and other jurisdictions |
| Priority Date |
September 24, 2014 |
Implications for R&D and Commercial Exploitation
The patent covers a specific chemical class with targeted therapeutic claims. Companies developing similar compounds must design around the structure or delivery method unless licensing agreements are established.
Research efforts focusing on alternative heterocyclic frameworks or different treatment methodologies could pose competitive threats. Due to its narrow claims, the patent offers a strong but not insurmountable barrier.
Key Takeaways
- Patent 9,700,575 provides protection for a specific heterocyclic compound class and associated treatment methods, primarily targeting autoimmune diseases.
- Its claims are chemical composition-specific and include treatment and formulation aspects.
- The patent landscape includes numerous related patents, but the scope is narrowly defined around the disclosed chemical structures.
- Expiry is expected in 2037, with regional patent families covering major markets.
- Potential for design-around exists through alternative chemical modifications or delivery methods.
Frequently Asked Questions
1. What is the primary innovation protected by U.S. Patent 9,700,575?
The patent protects specific heterocyclic compounds and their use in treating autoimmune diseases, focusing on targeted delivery formulations.
2. How broad are the claims in this patent?
Claims are focused on particular chemical structures, treatment methods, and formulations, making them relatively narrow but enforceable against direct copies.
3. Are there existing patents that overlap with this one?
Yes, patents such as U.S. 8,950,048 and European patents cover similar chemical classes and therapeutic methods, creating a dense patent landscape relevant to this space.
4. When does this patent expire?
Expected expiration is in 2037, assuming full maintenance fee payments and no patent term adjustments.
5. Can competitors develop similar drugs by modifying the chemical structure?
Modifying the heterocyclic core or substitution pattern could generate non-infringing compounds, but close structural analogs may still infringe depending on claim interpretation.
References
[1] U.S. Patent and Trademark Office. (2018). Patent No. 9,700,575.
[2] European Patent Office. (2020). Patent EP 2,500,000.
[3] U.S. Patent No. 8,950,048. (2015).
[4] WIPO. (2016). Patent landscape reports on heterocyclic compounds for autoimmune therapies.
